JPRN-jRCT2080224975已完成1 期
A Phase 1b Study to Assess the Safety, Tolerability, and Efficacy of TAS-120 (Futibatinib) in Combination with MK-3475 (Pembrolizumab) in Patients with Solid Tumors (MK3475 - 990)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 223
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Be willing and able to provide written informed consent for the trial.
- •Able to take medications orally.
- •Have a measurable disease per RECIST 1.1
- •Have adequate organ function value
- •Is willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other protocol procedures
- •Feasibility phase
- •Have histologically confirmed advanced or metastatic solid tumors
- •Be positive for FGF/FGFR abnormalities
- •Expansion phase
- •Have histologically confirmed advanced or metastatic esophageal carcinoma or non-small cell lung cancer
- •Have mRNA of FGFR 1, 2, 3, or 4 overexpression in tumor tissue sample (non-small cell lung cancer)
排除标准
- •Have a serious illness or medical conditions.
- •Have history of allergic reactions attributed to compounds of similar chemical or biologic composition to futibatinib and any drug similar to futibatinib in structure or class
研究者
相似试验
进行中（未招募）
1 期
A safety and efficacy study of the drug BGB-290 in combination with Temozolomide (TMZ) in patients with ovarian, breast, prostate, lung and stomach cancer.ocally Advanced or Metastatic Solid Tumors (ovarian cancer, triple negative breast cancer (TNBC), metastatic castration-resistant prostate cancer (mCRPC), small cell lung cancer (SCLC), and gastric cancer)EUCTR2017-001553-14-GBBeiGene USA, Inc.250
进行中（未招募）
1 期
A Study of Tarlatamab in Participants With Neuroendocrine Prostate Cancer (DeLLpro-300)JPRN-jRCT2031210415Tagashira Shuzo60
撤回
不适用
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaKahler's diseaseplasma cell myelomaRelapsed or Refractory Multiple Myeloma10018865NL-OMON46679Amgen3
进行中（未招募）
1 期
A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC WithFGFR2b Overexpression (FORTITUDE-201)Squamous-Cell Non-Small-Cell Lung CancerJPRN-jRCT2051220022Kaneda Hirokazu180
已完成
不适用
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects with De Novo or Treatment Emergent Neuroendocrine Prostate Cancerneuro-endocriene prostaatkankerNeuroendocrine Prostate Cancer10036958Prostate CancerNL-OMON51934Amgen3